Impressive improvement in overall survival when comparing 55 vs 33 months and progression-free survival (almost double) due to tolerable toxicity. Now in NCCN guidelines…
Improved outcome in patients with brain metastases, but only uses a small number. It is still promising.
Very interesting study using tarlatamab, a bispecific T-cell engager that directs T-cells to malignant cells expressing delta-like ligand 3 (DLL3). This was a dose escalation phase II, ORR was 40% and the longevity of response in responders was impressive for this disease. Further studies are sure to come.